Approximately 5.7 million Americans are afflicted with heart disease, with a reported 670,000 new cases and 300,000 deaths each year [1]. While the success rate of transplantation procedures continues to improve, organ availability remains limited. Left ventricular assist devices (LVADs) function as a bridge to transplant for advanced staged heart failure patients awaiting a donor heart. The devices have also been used, more recently, as a bridge to recovery by helping to unload the native ventricle. Along with pharmacological intervention, LVADs can act to help reverse pathological hypertrophy and recover normal myocardial function [2].

This content is only available via PDF.
You do not currently have access to this content.